Reviewer's report

Title: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

Version: 2 Date: 4 March 2010

Reviewer: Michael Pfleiderer

Reviewer's report:

European Medicines Agency's acronym is EMA, no longer EMEA

Minor Essential Revisions:

Preimmunization titres of study subjects should be indicated in table 2 as well as in the corresponding text paragraphs

A post hoc analysis as regards non-inferiority of seroprotection rates should be performed. Seroprotection is the more relevant parameter compared to GMTs. Clinical significance of the non-inferiority margin chosen should be well justified

Subanalyses should be performed based on a finer age stratification (e.g. 65 - 69, 70 - 89, 80 and above) as well as by dividing study subjects into groups with and without seroprotective titres pre-vaccination. This will provide the basis for a more comprehensive interpretation of potential differences as regards immunogenicity/efficacy of the two vaccines/routes of administration investigated.

Discussion should be modified/amended accordingly.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests